Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs
September 08 2020 - 4:01PM
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
today announced the appointment of Jonathan Biller to the role of
chief financial officer, head of legal and corporate affairs
effective September 11, 2020. Mr. Biller will replace Andrew Hirsch
who has served as the company’s chief financial officer since 2016.
Mr. Hirsch will depart the company this month to pursue another
opportunity and will remain a strategic advisor to Agios through
October 2020.
“With more than 30 years of broad, global treasury,
tax, legal and business development experience, I’m excited to have
Jonathan expand his leadership at Agios to include the role of
chief financial officer as we continue to advance our Agios 2025
strategic vision,” said Jackie Fouse, Ph.D., chief executive
officer of Agios. “I want to thank Andrew for his significant
contributions to Agios which have included evolving our finance,
business development, IT and facilities functions to support the
company’s growth and ensuring we’ve had sufficient capital to
invest in our productive research engine and broad clinical
portfolio.”
Mr. Biller joined Agios in November 2019 as chief
legal officer. Previously, Mr. Biller served as executive vice
president, general counsel at Celgene from July 2018 to November
2019 where he was responsible for Celgene’s global legal function.
He joined Celgene in 2011, serving as senior vice president, tax
and treasury, responsible for Celgene’s global tax and treasury
functions including the company’s capital allocation strategy and
tax policy. Prior to Celgene, Mr. Biller was general counsel, chief
tax officer and secretary from 2008 to 2011 at Bunge Limited, a
publicly traded agriculture and food company. Prior to Bunge, Mr.
Biller held roles of increasing responsibility at Alcon, Inc.
during which time it was a publicly traded company. He began his
legal career at Hopkins & Sutter rising to the level of partner
and was also partner at Foley & Lardner after the firms merged.
He holds a B.A. degree from Brown University and a J.D. from Yale
Law School.
About AgiosAgios is focused on
discovering and developing novel investigational medicines to treat
malignant hematology, solid tumors and rare genetic diseases
through scientific leadership in the field of cellular metabolism.
In addition to an active research and discovery pipeline across
these three therapeutic areas, Agios has two approved oncology
precision medicines and multiple first-in-class investigational
therapies in clinical and/or preclinical development. For more
information, please visit the company's website at
www.agios.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the expected benefits of Mr. Biller’s employment and
Agios’ strategic plans and focus. The words “anticipate,” “expect,”
“goal,” “hope,” “milestone,” “plan,” “potential,” “possible,”
“strategy,” “will,” “vision,” and similar expressions are intended
to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from Agios’ current expectations and beliefs. For
example, there can be no guarantee that any product candidate Agios
or its collaborators is developing will successfully commence or
complete necessary preclinical and clinical development phases, or
that development of any of Agios’ product candidates will
successfully continue. There can be no guarantee that any positive
developments in Agios’ business will result in stock price
appreciation. Management's expectations and, therefore, any
forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
important factors, including, without limitation: risks and
uncertainties related to the impact of the COVID-19 pandemic to
Agios’ business, operations, strategy, goals and anticipated
milestones, including its ongoing and planned research activities,
ability to conduct ongoing and planned clinical trials, clinical
supply of current or future drug candidates, commercial supply of
current or future approved products, and launching, marketing and
selling current or future approved products; Agios’ results of
clinical trials and preclinical studies, including subsequent
analysis of existing data and new data received from ongoing and
future studies; the content and timing of decisions made by the
U.S. FDA, the EMA or other regulatory authorities, investigational
review boards at clinical trial sites and publication review
bodies; Agios’ ability to obtain and maintain requisite regulatory
approvals and to enroll patients in its planned clinical trials;
unplanned cash requirements and expenditures; competitive factors;
Agios' ability to obtain, maintain and enforce patent and other
intellectual property protection for any product candidates it is
developing; Agios’ ability to maintain key collaborations; and
general economic and market conditions. These and other risks are
described in greater detail under the caption "Risk Factors"
included in Agios’ public filings with the Securities and Exchange
Commission. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Agios expressly
disclaims any obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
Contacts
Investors:Holly Manning,
617-844-6630Director, Investor RelationsHolly.Manning@agios.com
Media:Jessica Rennekamp,
857-209-3286Associate Director, Corporate
CommunicationsJessica.Rennekamp@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024